Siemens Medical Solutions Usa, Inc.

Eli Lilly and Company

Threshold Pharmaceuticals, Inc.

Umesh B Gangadharmath

Joseph C Walsh

Hartmuth C Kolb

Dhanalakshmi Kasi

Vani P Mocharla

Gang Chen

Tieming Zhao

Anjana Sinha

Kai Chen

Qianwa Liang

Eric Wang

Anna Katrin Szardenings

Peter J H Scott

Henry Clifton Padgett

Changhui Liu

Chul Yu

Farhad Karimi

Brian A Duclos

Zhiyong Gao

Thomas Lee Collier

Fanrong Mu

Chunfang Xia

Bing Wang

Wei Zhang

Arkadij M Elizarov

Carroll Edward Ball

Michael Schaefers

Sven Hermann

Andreas Faust

Guenter Haufe

Daniel Kurt Cashion

Vani P Mocharia

Ricardo Rodriguez

Robert M Yeh

Harmuth C Kolb

Klaus Kopka

Verena Hugenberg

Stefan Wagner

Hans-Joerg Breyholz

Peter JH Scott

Peter Jh Scott

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

PSMA imaging agents

The present application is directed to radiolabeled imaging agents comprising a radiolabel, and a substrate, pharmaceutical compositions comprising radiolabeled imaging agents, and methods of using the radiolabeled imaging agents. The present application is further directed to methods of preparing the radiolabeled imaging agent. Such imaging agents can used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).

Substrate based PET imaging agents

A system, apparatus, and method for transferring chemical solutions and synthesizing a tracer. For transferring chemical solutions, the system comprises a primary container; a secondary container; a first line in communication with the primary container and the secondary container. The first line facilitates the flow of gas and/or liquid between the primary container and the secondary container. A valve located upstream of the secondary container and downstream of the primary container regulates flow within the first line; a second line in communication with the secondary container. For synthesizing a tracer, the system includes a source of a solution having a radionuclide. A first container has a tracer precursor and is in communication with the source of solution.

System, device and method for preparing tracers and transferring materials during radiosynthesis

Compounds for targeting and agents for imaging, Prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

A formulation for stabilizing a radiopharmaceutical. The formulation includes a radiopharmaceutical (or a pharmaceutically acceptable salt thereof), a gas which has oxygen, a stabilizer, and a solvent.

Formulation, apparatus and method for stabilizing radiopharmaceuticals

Novel compounds and pharmaceutical compositions having MMP inhibitory activity are disclosed, which have been found to be particularly useful in the prevention, treatment and diagnostic imaging of diseases associated with an unpaired activity of MMP, amongst others MMP-2, MMP-8, MMP-9 and/or MMP-13 to name a few. The compounds of the present invention are useful for the prevention, the treatment and the in vivo diagnostic imaging of a range of disease states (inflammatory, malignant and degenerative diseases) where specific matrix metalloproteinases are known to be involved.

Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof

A method for synthesizing anF-labeled probe. The method includes a step of eluting an amount ofF with a first solvent which includes a predetermined amount of water and at least one organic solvent. In this step, theF elutes as anF solution. The method also includes a step of using theF solution to performF-labeling in the presence of at least one labeling reagent and at least one phase transfer catalyst so as to generate theF-labeled probe. In the method, there is no step of drying theF starting from a time when the eluting step is performed and ending at a time when theF-labeling step is performed.

Synthesis of 18F-labeled tracers in hydrous organic solvents

Disclosed here in are compounds and methods of diagnosing Alzheimer's Disease or a predisposition thereto in a mammal, the method comprising administering to the mammal a diagnostically effective amount of a radiolabeled compound, wherein the compound is selected from the group consisting of radiolabeled carbazoles and derivatives thereof and triazoles derivatives, allowing the compound to distribute into the brain tissue, and imaging the brain tissue, wherein an increase in binding of the compound to the brain tissue compared to a normal control level of binding indicates that the mammal is suffering from or is at risk of developing Alzheimer's Disease.

Imaging agents for detecting neurological dysfunction

Imaging agents of formulas (I)-(V) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formulas (I)-(V) capable of binding to tau proteins and &#x3b2;-amyloid peptides are presented herein. The invention also relates to methods of imaging A&#x3b2; and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formulas (I)-(V) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.

Imaging agents for detecting neurological disorders

Imaging agents of formula (I) and methods for detecting neurological disorders comprising administering ti a patient in need compounds of formula (I) capable of binding to tau proteins and &#x3b2;-amyloid peptides are presented herein. The invention also relates to methods of imaging A&#x3b2; and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formula (I) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.

Growing community of inventors

Los Angeles, CA, United States of America

Umesh B Gangadharmath